BD Diagnostics, Sparks, MD, announces the release of BBL™ CHROMagar™ Orientation medium, a chromogenic medium that uses enzymatic reactions to enable identification of E. coli and Enterococcus without additional confirmatory testing from urine specimens. E. coli and Enterococcus represent roughly 80% of the positive urine cultures in the laboratory. This nonselective, nutritive medium isolates and identifies both gram-positive and gram-negative pathogens with a single plate. BBL™ CHROMagar™ Orientation medium can substantially increase laboratory efficiency by reducing the number of plates to label, inoculate, incubate and read. This allows the microbiology laboratory to more effectively utilize limited labor resources, reduce the costs associated with confirmatory identification procedures and in many cases report results earlier.
BBL™ CHROMagar™ Orientation medium offers fast identification of common urinary pathogens and contains a unique formulation to inhibit the swarming of Proteus spp. This medium also enables more efficient screening of suspect urine samples because it provides presumptive identification of Staphylococcus saprophyticus and Streptococcus agalactiae, as well as Klebsiella-Enterobacter-Serratia and the Proteus-Morganella-Providencia groups. This provides improved detection of mixed urine cultures for quicker assessment of contaminated samples.
For more information on BBL™ CHROMagar™ Orientation medium, please call 1-800-638-8663, or contact your local BD Diagnostics sales representative.
CHROMagar is a trademark of Dr. A. Rambach.
This press release may contain certain forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, products and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; changes in interest or foreign currency exchange rates; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; increases in energy costs; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; and changes in healthcare or other governmental regulation; issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.
